🇺🇸·23h agoIndustry
Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years
Publisher
B
Bristol-Myers Squibb News
USA
This page provides publisher metadata, and related coverage to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Bristol-Myers Squibb News
- Region
- USA
- Scope
- Industry
- Published
- September 17, 2026
Publisher context, original article off-platform
This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.
Source route
Continue on bristolmyers2016ir.q4web.com
Leave the platform to read the original full article on the publisher site.
Source: Bristol-Myers Squibb News
Scope: Industry
Related coverage
More related coverage
Interpharma Switzerland/1d ago
Was einen starken Forschungsstandort ausmacht
Chugai Pharmaceutical News/1d ago
ルンスミオに関するロシュ社の発表について（再発又は難治性濾胞性リンパ腫に対する国際共同第III相CELESTIMO試験のデータ）
Chugai Pharmaceutical/1d ago
Roche Announces Phase III CELESTIMO Study Results for Lunsumio in Relapsed or Refractory Follicular Lymphoma
Roche Newsroom/1d ago